{
  "id": 16784822,
  "title": "Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue",
  "url": "https://urgent.news/2026/10/27/amgen-vs-vertex-pharmaceuticals-massive-pharmaceutical-scale-vs",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-27T19:25:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/coverage/charts/2026/10/27/amgen-vs-vertex-pharmaceuticals-massive-pharmaceutical-scale-vs-steady-drug-revenue/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Amgen, a major pharmaceutical company, focuses on oncology and cardiovascular diseases, while Vertex Pharmaceuticals specializes in cystic fibrosis treatments. Both companies experienced a seasonal revenue increase in the fourth quarter, due to patients filling their prescriptions after resetting their health insurance deductibles. Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals, and its FDA expanded the use of Casgevy to include patients as young as two years old. The FDA also granted Breakthrough Therapy Designation for a new cystic fibrosis treatment, which could potentially generate $4 billion to $7 billion in annual sales. Amgen, on the other hand, has six drug franchises that generate over $1 billion in annual revenue, and recently reached an agreement with the U.S. government to lower drug prices by approximately 60% to 80%.",
  "summary": "Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.",
  "key_points": [
    "Amgen specializes in oncology and cardiovascular diseases",
    "Vertex Pharmaceuticals acquires Crinetics and expands Casgevy use",
    "Amgen secures $4-$7 billion annual sales potential for new cystic fibrosis treatment"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}